Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest NmVac4-A/C/Y/W-135 Stories

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2013-12-26 08:23:10

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons...

2013-12-09 08:27:23

-- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including infants, children one to four years and adolescents who are at the greatest risk of infection2,3 -- MenB is the most common type of meningitis in Canada4. It is responsible for 80 per cent of meningococcal cases in infants under one year of age, 67 per cent in one to four...

2013-12-09 00:20:38

-- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including infants, children one to four years and adolescents who are at the greatest risk of infection2,3 -- MenB is the most common type of meningitis in Canada4. It is responsible for 80 per cent of meningococcal cases in infants under one year of age, 67 per cent in one to four...

2013-09-24 13:21:31

Clinical trial A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age, according to a clinical trial published in CMAJ (Canadian Medical Association Journal). The 4CMenB vaccine, an important breakthrough in the fight against childhood meningitis, was recently licensed in Europe and is...

2013-09-13 08:19:19

No cases of serogroup A meningococcal meningitis following vaccination of almost 2 million people; incidence of all cases of meningitis reduced by 94 percent Evaluation of the effectiveness of a mass vaccination campaign with a new meningitis serogroup A vaccine, PsA-TT, in sub-Saharan Africa found that it had a dramatic impact on cases of serogroup meningitis and on carriage of the disease-causing bacteria in the throat, according to new research published in The Lancet. Authors from...

2013-08-01 20:21:18

- Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children[2,3] CAMBRIDGE, Mass., Aug. 1, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo(®) (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) to help prevent meningococcal disease caused by four strains of the bacterium Neisseria...

2013-06-13 08:25:25

- "Get in the Game" urges parents to take action and vaccinate against meningococcal disease in advance of the upcoming sports season SILVER SPRINGS, Md. and SWIFTWATER, Pa., June 13, 2013 /PRNewswire/ -- Voices of Meningitis, a public health initiative of the National Association of School Nurses (NASN) in collaboration with Sanofi Pasteur, announced today the launch of Get in the Game: Keeping Teens Healthy, a new program to help educate parents on the danger and prevention of...

2012-12-27 08:25:04

HOUSTON, Dec. 27, 2012 /PRNewswire/ -- Parents, what are you waiting for? On January 1, 2012, the Schanbaum/Williams law required all college students under age 30 and attending class on a Texas campus, to be vaccinated against bacterial meningitis prior to school entry. The intent is to protect our college students from this horrible disease. With the start of the spring semester approaching in the next few weeks, it is imperative for students to be vaccinated before registering. Anna C....